Sheet-Shaped Cell Culture Enhances Bioadhesiveness

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for treating peripheral arterial disease, such as administering mononuclear cell fractions or mesenchymal stem cells, face challenges with insufficient bioadhesiveness at the administration site, limiting their effectiveness in promoting angiogenesis.

Innovation Solution

A sheet-shaped cell culture with myoblast cells and an extracellular matrix on its outer surface is administered, enhancing bioadhesiveness and promoting angiogenesis by providing a stable matrix for cell attachment and prolonged survival at the treatment site.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If single-cell form cells are administered to treat peripheral arterial disease, then the treatment can be easily applied, but the bioadhesiveness at the administration site is insufficient

Engineering Contradiction:
Improveease of administrationVSAvoidbioadhesiveness
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent combines multiple cells into a clustered cell construct rather than administering single cells. This merging of cells creates a unified therapeutic unit that maintains ease of administration through injection while significantly improving bioadhesiveness through collective cell-matrix interactions and cell-to-cell adhesion mechanisms.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The invention uses a composite structure consisting of cells embedded in an extracellular matrix framework. This composite material approach provides both the ease of injection (through the matrix structure) and enhanced bioadhesiveness (through the matrix-cell interface and cellular components working together).

Inventive Principle:
Principle #40Composite materials

2Productivity

If cell therapy is administered to promote angiogenesis, then blood flow improvement is achieved, but the duration of therapeutic effect is limited due to insufficient cell survival

Engineering Contradiction:
Improveangiogenesis promotionVSAvoidduration of therapeutic effect
Core Design Contradiction:
ProductivityVSDuration of action of moving object

Solution Approach 1:

The extracellular matrix is prepared in advance and serves as a pre-established supportive framework before cells are introduced. This preliminary structure provides immediate survival cues and protection to transplanted cells, enhancing their long-term persistence and continuous angiogenic activity at the administration site.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The extracellular matrix acts as an intermediary between the administered cells and the host tissue environment. It mediates cell survival, integration, and function by providing structural support, biochemical signals, and physical protection, thereby extending the duration of therapeutic effect through improved cell engraftment and sustained angiogenesis.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP4049666B1Cell culture for treating peripheral arterial disease
Publication Date: 2024.10.30 TERUMO KK
  • EP4049666B1 patent drawingFigure 1
  • EP4049666B1 patent drawingFigure 2A~2B
  • EP4049666B1 patent drawingFigure 2C~3A

AI summary

An object of the present invention is to provide a cell culture for treating peripheral arterial disease, a method for producing the cell culture, a method for treating peripheral arterial disease using the cell culture, and the like. According to the present specification, a cell culture with a size of 100 to 500 µm having an extracellular matrix on an outer surface of the cell culture, and the like are provided, and the above problem has been solved.